BioCentury
ARTICLE | Emerging Company Profile

GrayBug: Long view in AMD

GrayBug developing extended-release anti-angiogenic therapy for AMD

July 22, 2013 7:00 AM UTC

GrayBug LLC is looking to treat age-related macular degeneration by combining two technologies - a small molecule therapeutic and an extended-release polymer carrier - to achieve sustained inhibition of hypoxia-inducible factor 1 activity in the retina.

Hypoxia-inducible factor 1 (HIF1) is a transcription factor that upregulates VEGF and other angiogenic proteins in response to low oxygen levels...